Post by Novocure

Novocure will present new research about Tumor Treating Fields (TTFields) therapy at the 2026 American Society of Clinical Oncology (#ASCO26) Annual Meeting, being held May 29 – June 2 in Chicago, Illinois:   TTFields therapy with maintenance temozolomide and pembrolizumab versus TTFields with maintenance temozolomide and placebo for newly diagnosed glioblastoma: The Phase 3 EF-41/KEYNOTE D58 trial. https://lnkd.in/eMmGe-xP   TTFields therapy in patients with newly diagnosed glioblastoma and poor performance status: Real-world analysis of patients treated in the US. https://lnkd.in/ev5WPavq   Efficacy and safety by tumor location in the phase 3 PANOVA-3 trial of TTFields with gem/nab-pac in locally advanced pancreatic adenocarcinoma. https://lnkd.in/eEtiKX-e